EW raises guidance
Edwards Lifesciences reported double-digit sales growth and adjusted EPS, raised full-year sales guidance plus TAVR and TMTT outlooks, and the release did not include consensus figures to confirm a beat or miss.
Sources: https://stockanalysis.com/stocks/ew/transcripts/653920-q2-2026/
Previous verdicts for EW
- EW beats, lifts view — 2026-11-05
- Idiosyncratic Selling — 2026-05-08
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works